Dr. Xavier Barril, Chief Scientific Officer, Gain Therapeutics, and Hartaj Singh, Managing Director and Senior Analyst, Oppenheimer & Co. Inc., Join BioTalk to discuss Artificial Intelligence and Machine Learning in Drug Discovery Wall Street’s Views on this Exciting Science.
Listen Now via Apple https://apple.co/3z1rdqN, Google https://bit.ly/2X2pNPu, Spotify https://spoti.fi/2Vn2Ohx, and TuneIn https://bit.ly/38PJn41.
Hartaj Singh is Managing Director and Senior Analyst covering Biotechnology. Prior to joining Oppenheimer, Hartaj was Managing Director and Senior Biotechnology Analyst at BTIG Securities. Hartaj began his sell-side career at Lehman Brothers and subsequently moved to the buyside covering Biotechnology at Visium Asset Management and Tecumseh Partners. He began his career as a Clinical Trial Project Manager for ClinTrials Research and also worked as a Strategic Analysis Manager for Johnson and Johnson, both of which give him critical experience in clinical trial design. Hartaj has a B.A. in Biology from Case Western Reserve University and also did extensive graduate work in Computational Neurobiology. He also holds an M.B.A. from Duke University's Fuqua School of Business.
Dr. Xavier Barril has served as chief scientific officer since January 2018. Dr. Barril has over 18 years of experience in computational chemistry and drug discovery. Since 2005, Dr. Barril has been with University of Barcelona as ICREA professor. Prior to joining Gain, Dr. Barril served as co-founder & scientific advisor to Minoryx Therapeutics. He has also developed his career at Vernalis as a senior investigator. Among other discoveries, Dr. Barril is co-inventor of the Hsp90 inhibitors that Vernalis licensed to Novartis and which underwent clinical trials. He is the inventor of the innovative platform technology that Gain Therapeutics is exploiting to identify new structurally targeted allosteric regulators. Dr. Barril has co-authored more than 80 scientific publications and 10 patents. Dr. Barril received a Ph.D. in Biochemistry from the University of Barcelona.